Publications by authors named "David Fajgenbaum"

Claim this Profile
A
A patient-derived CABIN1 mutation recapitulates features of idiopathic multicentric Castleman disease in a mouse model.
Dorottya Laczko, Patricia Tsao, Ruth-Anne Pai, Joseph Zinski, Michael V Gonzalez, David C Fajgenbaum

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Ferritin, C-Reactive Protein, and Soluble CD25 Distinguish TAFRO From HLH.
Steven Rowe, Mariam Goubran, Mateo Sarmiento Bustamante, Saishravan Shyamsundar, Bridget Austin, David C Fajgenbaum

Am J Hematol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medicines, Diseases, Indications, and Contraindications (MeDIC): a foundational resource to support drug repurposing.
Marcello DeLuca, Nico Matentzoglu, Elliott Sharp, Jane Li, Charlie Hempstead, David C Fajgenbaum

Nucleic Acids Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dysregulated lymphocyte localization in idiopathic multicentric Castleman disease.
Melanie D Mumau, Michael V Gonzalez, Katherine S Forsyth, M Betina Pampena, Abiola H Irvine, David C Fajgenbaum

bioRxiv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International Consensus Histopathological Criteria for Subtyping Idiopathic Multicentric Castleman Disease Based on Machine Learning Analysis.
Midori Filiz Nishimura, Tomoka Haratake, Yoshito Nishimura, Asami Nishikori, Remi Sumiyoshi, David C Fajgenbaum

Am J Hematol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinct interleukin-6 production in IPL and TAFRO subtypes of idiopathic multicentric Castleman disease.
Asami Nishikori, Midori Filiz Nishimura, Yoshito Nishimura, Rio Yamada, Tomoka Haratake, David C Fajgenbaum

Haematologica· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Involvement of PI3K-Akt Signaling in the Clinical and Pathological Findings of Idiopathic Multicentric Castleman Disease-Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis, and Organomegaly and Not Otherwise Specified Subtypes.
Tomoka Haratake, Midori Filiz Nishimura, Asami Nishikori, Michael V Gonzalez, Daisuke Ennishi, David C Fajgenbaum

Mod Pathol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interferon-γ sparks inflammatory fire in Castleman disease.
Frits van Rhee, David Fajgenbaum

Blood· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expert Perspective: Diagnosis and Treatment of Castleman Disease.
Luke Y C Chen, Lu Zhang, David C Fajgenbaum

Arthritis Rheumatol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Common connective tissue disorder and anti-cytokine autoantibodies are enriched in idiopathic multicentric castleman disease patients.
Allan Feng, Michael V Gonzalez, Muge Kalaycioglu, Xihui Yin, Melanie Mumau, David C Fajgenbaum

Front Immunol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
to: Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease.
Mateo Sarmiento Bustamante, Sheila K Pierson, Yue Ren, Adam Bagg, Joshua D Brandstadter, David C Fajgenbaum

Haematologica· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rare Disease Drug Repurposing.
Sally Nijim, Ania Korsunska, Joseph Zinski, Sarah E Bolden, Mary Zuccato, David C Fajgenbaum

JAMA Netw Open· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the Clinical Diversity of Castleman Disease and TAFRO Syndrome: A Japanese Multicenter Study on Lymph Node Distribution Patterns.
Mizuna Otsuka, Tomohiro Koga, Remi Sumiyoshi, Shoichi Fukui, Yuko Kaneko, David C Fajgenbaum

Am J Hematol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry.
Sheila K Pierson, Joshua D Brandstadter, Drew A Torigian, Adam Bagg, Mary Jo Lechowicz, David C Fajgenbaum

Blood Adv· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying and Targeting TNF Signaling in Idiopathic Multicentric Castleman's Disease.
Melanie D Mumau, Michael V Gonzalez, Chunyu Ma, Abiola H Irvine, Mateo Sarmiento Bustamante, David C Fajgenbaum

N Engl J Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pioneering a new field of computational pharmacophenomics to unlock the life-saving potential of existing medicines.
David C Fajgenbaum, Sally Nijim, Grant Mitchell, Matej Macak, Chris Bizon

Lancet Haematol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No evidence for active viral infection in unicentric and idiopathic multicentric Castleman disease by Viral-Track analysis.
Ira Miller, Melanie D Mumau, Saishravan Shyamsundar, Mateo Sarmiento Bustamante, Pedro Horna, David C Fajgenbaum

Sci Rep· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Idiopathic multicentric Castleman disease with marrow fibrosis and extramedullary hematopoiesis.
Marley Blommers, Sorin Selegean, Richard K Wood, Mateo Sarmiento Bustamante, Saishravan Shyamsundar, David C Fajgenbaum

Eur J Haematol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying Castleman disease from non-clonal inflammatory causes of generalized lymphadenopathy.
Sally Nijim, David C Fajgenbaum

Hematology Am Soc Hematol Educ Program· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CRP and sCD25 help distinguish between adult-onset Still's disease and HLH.
Madelaine Beckett, Caroline Spaner, Mariam Goubran, John Wade, Juan Antonio Avina-Zubieta, David C Fajgenbaum

Eur J Haematol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The clinical picture of Castleman disease: a systematic review and meta-analysis.
Christian Hoffmann, Eric Oksenhendler, Sarah Littler, Lisa Grant, Karan Kanhai, David C Fajgenbaum

Blood Adv· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Cytokine Storm of Multicentric Castleman Disease.
David C Fajgenbaum

Adv Exp Med Biol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increase in Vascular Endothelial Growth Factor (VEGF) Expression and the Pathogenesis of iMCD-TAFRO.
Gordan Srkalovic, Sally Nijim, Maya Blanka Srkalovic, David Fajgenbaum

Biomedicines· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insights into the etiology of Castleman disease.
Frits van Rhee, David Fajgenbaum

Blood· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Castleman disease patients report mild COVID-19 symptoms and mount a humoral response to SARS-CoV-2 vaccination.
Saishravan Shyamsundar, Sheila K Pierson, Caoilfhionn M Connolly, Mayan Teles, Dorry L Segev, David C Fajgenbaum

Blood Neoplasia· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis